Q2 2025 Gilead Sciences Inc Earnings Call Transcript
Key Points
- Gilead Sciences Inc (GILD) reported a strong second quarter with product sales of $7.1 billion, a 2% year-over-year increase.
- The FDA approval of Yeztugo, a twice-yearly injection for HIV prevention, marks a significant milestone and has been well-received in its early launch phase.
- Biktarvy sales grew 9% year-over-year to $3.5 billion, and Descovy sales increased 35% year-over-year to $653 million, highlighting robust growth in the HIV segment.
- Trodelvy showed positive Phase 3 results in metastatic triple-negative breast cancer, potentially expanding its use to the first-line setting.
- Gilead Sciences Inc (GILD) increased its full-year revenue and EPS guidance, reflecting strong commercial execution and operating expense discipline.
- Veklury sales declined 44% year-over-year due to fewer COVID-19 related hospitalizations, impacting overall product sales growth.
- The company faces competitive headwinds in its cell therapy segment, with a 7% year-over-year decline in sales.
- HCV sales decreased following a strong second quarter in 2024, reflecting lower average realized price and patient starts.
- Despite early success, the Yeztugo launch faces challenges in achieving broad access and reimbursement, with expectations for coverage to take time.
- The impact of Medicare Part D redesign is expected to affect the HIV business by approximately $900 million in 2025.
Good afternoon, everyone, and welcome to Gilead's second quarter 2025 earnings conference call. My name is Rebecca, and I'll be today's host. (Operator instructions)
Now I'll hand the call over to Jackie Ross, Senior Vice President of Treasury and Investor Relations.
Thank you, Rebecca. Just after market closed today, we issued a press release with earnings results for the second quarter of 2025. The press release, slides, and supplementary data are available on the Investors Section of our website at gilead.com.
The speakers on today's call will be our Chairman and Chief Executive Officer, Daniel O'Day; our Chief Commercial Officer, Johanna Mercier; our Chief Medical Officer, Dietmar Berger; and our Chief Financial Officer, Andrew Dickinson.
After that, we'll open the call to Q&A where the team will be joined by Cindy Perettie, the Executive Vice President of Kite.
Let me remind you that we will be making forward-looking
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
